Inspire Medical Systems, Inc. has announced its financial results for the third quarter of 2026, revealing a revenue decline primarily attributed to challenges in coding and reimbursement. The company reported a revenue of $206.7 million, down 7.9% compared to the same quarter last year. Despite these challenges, Inspire expressed optimism about future growth driven by new coding initiatives.

Inspire Medical Systems, Inc. operates within the surgical and medical instruments and apparatus sector, specifically focusing on innovative solutions for obstructive sleep apnea. The company trades on the New York Stock Exchange under the ticker symbol INSP. Its recent filings include a Schedule 13G/A on October 30, 2026, and multiple Form 4 filings on October 16, 2026.

According to the recent SEC filing, Inspire Medical Systems reported a third quarter diluted EPS of $(0.84), with an adjusted diluted EPS of $0.14. The filing also highlighted that the company experienced an operating loss of $28.7 million, with an operating margin of (13.9)%. Operating expenses rose by 12.8% to $206.6 million, largely due to restructuring charges and legal expenses.

The financial results may impact various stakeholders, including investors, analysts, and healthcare providers who rely on Inspire's products. The anticipated new Category I CPT codes for single lead hypoglossal nerve stimulation, effective January 1, 2028, could enhance reimbursement clarity and patient access, potentially benefiting the entire industry.

Looking ahead, Inspire plans to continue its education initiatives and strategic priorities to navigate through the current challenges. The filing does not specify what happens next, but the company is actively engaging with investors and analysts in meetings scheduled for November and December 2026.